AssureRx Health Launches Personalized Medicine Test for ADHD

Posted on by

MASON, Ohio, May 7, 2012 /PRNewswire/ --AssureRx Health, Inc. today announced it has launched a personalized medicine test for the growing number of children and adults diagnosed with attention deficit hyperactivity disorder (ADHD). The new pharmacogenomic test can assist clinicians with important medication decisions that result from genomic differences in how individual patients tolerate ADHD medications.

GeneSightRx ADHD analyzes variations in three genes that influence how a patient might metabolize certain medications used to treat ADHD in children and adults. Understanding a patient's unique genomic profile may help a clinician individualize a patient's medication selection and avoid side effects that often occur with these medications. The test provides objective, evidence-based information for clinicians to personalize medication selection for each patient.

The GeneSightRx ADHD analysis is based on pharmacogenomics, FDA-approved manufacturer's drug labels, published peer reviewed research, and proven pharmacology. The new ADHD test adds to the company's treatment decision support products that include GeneSightRx Psychotropic, a psychiatric pharmacogenomic product that tests important genomic variants affecting metabolism to psychiatric medications for individual patients.

ADHD diagnoses increased 66 percent from 6.2 million in 2000 to 10.4 million in 2010, according to a study published in the March/April 2012 issue of Academic Pediatrics. ADHD is the most common childhood disorder and can continue into adulthood. Symptoms of ADHD include an inability to stay focused or pay attention, difficulty controlling behavior, and hyperactivity.

"ADHD is a neurobehavioral disorder affecting millions of children and adults. With the introduction of GeneSightRx ADHD, clinicians now have an objective, evidence-based tool for individualizing ADHD medications," said James S. Burns, president and CEO of AssureRx Health."Our goal is to build a portfolio of innovative pharmacogenomic and other treatment decision support products to help physicians individualize the treatment of patients with neuropsychiatric and other disorders."

When a clinician orders the test, a DNA sample is taken from the patient with a simple, non-invasive cheek swab. The specimen is sent overnight to AssureRx Health's CLIA-certified and CAP-accredited laboratory. The ordering clinician receives the patient report via a secure online portal that presents the patient's genomic information in an easy-to-read and clinically actionable format.

About GeneSightRx

GeneSightRx is a laboratory developed genomic test that uses cutting edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders. The results of the GeneSightRx report can help a clinician understand the way a patient's unique genomic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual's response to drug treatments, FDA approved manufacturer's drug labels, peer-reviewed scientific and clinical publications, and proven drug pharmacology. Quick turnaround time, combined with a customized report of the patient's genomic makeup, clinical experience, and other factors can help a physician make personalized drug treatment choices for each individual patient. To learn more about pharmacogenomics and GeneSightRx, please click here. Be sure to watch the educational video on our YouTube channel.

About AssureRx Health

AssureRx Health, Inc. is a personalized medicine company that specializes in pharmacogenomics dedicated to helping clinicians determine the right drug for individual patients suffering from neuropsychiatric and other disorders. The GeneSightRx analysis is based on pharmacogenomics the study of the genomic factors that influence an individual's response to drug treatments, using FDA approved manufacturers' drug labels, scientific and clinical peer-reviewed publications, and proven pharmacology. The company was founded to commercialize industry-leading personalized medicine technology. To learn more about pharmacogenomics and GeneSightRx, visit http://www.assurerxhealth.com.

Read the original:
AssureRx Health Launches Personalized Medicine Test for ADHD

Affy Says Genotyping Arrays a Bright Spot amid Q1 Revenue Drop; Plans to Close eBioscience Buy in Q2

Posted on by

Trovagene has named Carlo Croce to serve on its scientific advisory board. Croce is director of the Human Cancer Genetics Program and the Genetics Institute at The Ohio State University, and he is John W. Wolfe Chair in Human Cancer Genetics.

Population Genetics has named Alan Schafer as its new CEO. Schafer is an adjunct professor at Imperial College London Business School and was previously the Wellcome Trust's director of science funding. Before that he served as global vice president of technology development at GlaxoSmithKline and co-founded Hexagen, a functional genomics company that was acquired by Incyte.

Pacific Biosciences said this week that Karen Bray has joined the company as VP of North American Sales. Bray previously was a sequencing sales leader at Life Technologies selling Ion Torrent and SOLiD systems in the Southeast and Mid-Atlantic regions, and before that she held sales posts at Beckman Coulter, Fisher Scientific, and Whatman.

More here:
Affy Says Genotyping Arrays a Bright Spot amid Q1 Revenue Drop; Plans to Close eBioscience Buy in Q2

NIH Awards $850K in Grant Funding for miRNA Drug Research in April

Posted on by

Pacific Biosciences said this week that Karen Bray has joined the company as VP of North American Sales. Bray previously was a sequencing sales leader at Life Technologies selling Ion Torrent and SOLiD systems in the Southeast and Mid-Atlantic regions, and before that she held sales posts at Beckman Coulter, Fisher Scientific, and Whatman.

Real Time Genomics has appointed Steve Lombardi to be company president and CEO, the genomic analysis software company said this week. Lombardi was president and then CEO of Helicos Biosciences between 2006 and 2010, and he was a senior executive involved in corporate development and business management at Affymetrix between 2002 and 2006. He also held several sales and management positions at Applied Biosystems in product, sales, and business management from 1986 to 2002.

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

Read the original here:
NIH Awards $850K in Grant Funding for miRNA Drug Research in April

UK Team Links Sense Strand 'Mirror microRNA' in Mammalian Cells to Neuronal Function

Posted on by

Pacific Biosciences said this week that Karen Bray has joined the company as VP of North American Sales. Bray previously was a sequencing sales leader at Life Technologies selling Ion Torrent and SOLiD systems in the Southeast and Mid-Atlantic regions, and before that she held sales posts at Beckman Coulter, Fisher Scientific, and Whatman.

Real Time Genomics has appointed Steve Lombardi to be company president and CEO, the genomic analysis software company said this week. Lombardi was president and then CEO of Helicos Biosciences between 2006 and 2010, and he was a senior executive involved in corporate development and business management at Affymetrix between 2002 and 2006. He also held several sales and management positions at Applied Biosystems in product, sales, and business management from 1986 to 2002.

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

Original post:
UK Team Links Sense Strand 'Mirror microRNA' in Mammalian Cells to Neuronal Function

Mirna Reports on Role of miR-34a in B Cell Lymphoma, Expands Planned Phase I Beyond Liver Cancer

Posted on by

Pacific Biosciences said this week that Karen Bray has joined the company as VP of North American Sales. Bray previously was a sequencing sales leader at Life Technologies selling Ion Torrent and SOLiD systems in the Southeast and Mid-Atlantic regions, and before that she held sales posts at Beckman Coulter, Fisher Scientific, and Whatman.

Real Time Genomics has appointed Steve Lombardi to be company president and CEO, the genomic analysis software company said this week. Lombardi was president and then CEO of Helicos Biosciences between 2006 and 2010, and he was a senior executive involved in corporate development and business management at Affymetrix between 2002 and 2006. He also held several sales and management positions at Applied Biosystems in product, sales, and business management from 1986 to 2002.

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

See the original post here:
Mirna Reports on Role of miR-34a in B Cell Lymphoma, Expands Planned Phase I Beyond Liver Cancer

People in the News: Marc Grodman, Charles Todd, Steve Lombardi

Posted on by

Pacific Biosciences said this week that Karen Bray has joined the company as VP of North American Sales. Bray previously was a sequencing sales leader at Life Technologies selling Ion Torrent and SOLiD systems in the Southeast and Mid-Atlantic regions, and before that she held sales posts at Beckman Coulter, Fisher Scientific, and Whatman.

Real Time Genomics has appointed Steve Lombardi to be company president and CEO, the genomic analysis software company said this week. Lombardi was president and then CEO of Helicos Biosciences between 2006 and 2010, and he was a senior executive involved in corporate development and business management at Affymetrix between 2002 and 2006. He also held several sales and management positions at Applied Biosystems in product, sales, and business management from 1986 to 2002.

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

Read more here:
People in the News: Marc Grodman, Charles Todd, Steve Lombardi

New Products: UCSC Cancer Genomics Hub

Posted on by

Pacific Biosciences said this week that Karen Bray has joined the company as VP of North American Sales. Bray previously was a sequencing sales leader at Life Technologies selling Ion Torrent and SOLiD systems in the Southeast and Mid-Atlantic regions, and before that she held sales posts at Beckman Coulter, Fisher Scientific, and Whatman.

Real Time Genomics has appointed Steve Lombardi to be company president and CEO, the genomic analysis software company said this week. Lombardi was president and then CEO of Helicos Biosciences between 2006 and 2010, and he was a senior executive involved in corporate development and business management at Affymetrix between 2002 and 2006. He also held several sales and management positions at Applied Biosystems in product, sales, and business management from 1986 to 2002.

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

See the original post:
New Products: UCSC Cancer Genomics Hub

Q&A: CeGaT's Saskia Biskup on Building an NGS-Based Clinical Sequencing Lab

Posted on by

Pacific Biosciences said this week that Karen Bray has joined the company as VP of North American Sales. Bray previously was a sequencing sales leader at Life Technologies selling Ion Torrent and SOLiD systems in the Southeast and Mid-Atlantic regions, and before that she held sales posts at Beckman Coulter, Fisher Scientific, and Whatman.

Real Time Genomics has appointed Steve Lombardi to be company president and CEO, the genomic analysis software company said this week. Lombardi was president and then CEO of Helicos Biosciences between 2006 and 2010, and he was a senior executive involved in corporate development and business management at Affymetrix between 2002 and 2006. He also held several sales and management positions at Applied Biosystems in product, sales, and business management from 1986 to 2002.

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

Read the rest here:
Q&A: CeGaT's Saskia Biskup on Building an NGS-Based Clinical Sequencing Lab

Australian Project to Sequence 10K Tumors, Study Cost Effectiveness of Personalized Oncology

Posted on by

Pacific Biosciences said this week that Karen Bray has joined the company as VP of North American Sales. Bray previously was a sequencing sales leader at Life Technologies selling Ion Torrent and SOLiD systems in the Southeast and Mid-Atlantic regions, and before that she held sales posts at Beckman Coulter, Fisher Scientific, and Whatman.

Real Time Genomics has appointed Steve Lombardi to be company president and CEO, the genomic analysis software company said this week. Lombardi was president and then CEO of Helicos Biosciences between 2006 and 2010, and he was a senior executive involved in corporate development and business management at Affymetrix between 2002 and 2006. He also held several sales and management positions at Applied Biosystems in product, sales, and business management from 1986 to 2002.

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

View post:
Australian Project to Sequence 10K Tumors, Study Cost Effectiveness of Personalized Oncology

Reporting 27 Percent Q3 Jump, Myriad Outlines Three-Pronged Plan for Diversifying Revenue Base

Posted on by

Pacific Biosciences said this week that Karen Bray has joined the company as VP of North American Sales. Bray previously was a sequencing sales leader at Life Technologies selling Ion Torrent and SOLiD systems in the Southeast and Mid-Atlantic regions, and before that she held sales posts at Beckman Coulter, Fisher Scientific, and Whatman.

Real Time Genomics has appointed Steve Lombardi to be company president and CEO, the genomic analysis software company said this week. Lombardi was president and then CEO of Helicos Biosciences between 2006 and 2010, and he was a senior executive involved in corporate development and business management at Affymetrix between 2002 and 2006. He also held several sales and management positions at Applied Biosystems in product, sales, and business management from 1986 to 2002.

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

See original here:
Reporting 27 Percent Q3 Jump, Myriad Outlines Three-Pronged Plan for Diversifying Revenue Base

EdgeBio Receives CLIA Certification, Launches Clinical Exome Test

Posted on by

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

Knome has added some new faces to its executive team, naming Jay Therrien as senior VP and head of global sales, Charles Abdalian as chief financial officer, and Adam Rosenberg as senior VP and head of corporate development.

Therrien was VP of commercial operations and sequencing at Life Technologies, and also had spent five years in various sales leadership roles at Illumina. Abdalian recently was senior VP and CFO of Molecular Insight Pharmaceuticals, and he was senior VP of finance and CFO at Coley Pharmaceutical. Rosenberg previously was an adviser for emerging life sciences companies, co-founder of Clean Membranes, and CEO of Link Medicine.

The company also has appointed Hugh Reinhoff to serve on its scientific advisory board. Reinhoff is currently a managing director of Life Science Venture Partners, an adjunct scientist at the Children's Hospital Oakland Research Institute, and CEO of FerroKin BioSciences.

The rest is here:
EdgeBio Receives CLIA Certification, Launches Clinical Exome Test

New Products: Integromics' OmicsOffice; GenBank version 189

Posted on by

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

Knome has added some new faces to its executive team, naming Jay Therrien as senior VP and head of global sales, Charles Abdalian as chief financial officer, and Adam Rosenberg as senior VP and head of corporate development.

Therrien was VP of commercial operations and sequencing at Life Technologies, and also had spent five years in various sales leadership roles at Illumina. Abdalian recently was senior VP and CFO of Molecular Insight Pharmaceuticals, and he was senior VP of finance and CFO at Coley Pharmaceutical. Rosenberg previously was an adviser for emerging life sciences companies, co-founder of Clean Membranes, and CEO of Link Medicine.

The company also has appointed Hugh Reinhoff to serve on its scientific advisory board. Reinhoff is currently a managing director of Life Science Venture Partners, an adjunct scientist at the Children's Hospital Oakland Research Institute, and CEO of FerroKin BioSciences.

Read more here:
New Products: Integromics' OmicsOffice; GenBank version 189

IP Watch: Abbott, University of Utah, Fluidigm, Roche, Quest, and Others Win US Patents

Posted on by

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

Knome has added some new faces to its executive team, naming Jay Therrien as senior VP and head of global sales, Charles Abdalian as chief financial officer, and Adam Rosenberg as senior VP and head of corporate development.

Therrien was VP of commercial operations and sequencing at Life Technologies, and also had spent five years in various sales leadership roles at Illumina. Abdalian recently was senior VP and CFO of Molecular Insight Pharmaceuticals, and he was senior VP of finance and CFO at Coley Pharmaceutical. Rosenberg previously was an adviser for emerging life sciences companies, co-founder of Clean Membranes, and CEO of Link Medicine.

The company also has appointed Hugh Reinhoff to serve on its scientific advisory board. Reinhoff is currently a managing director of Life Science Venture Partners, an adjunct scientist at the Children's Hospital Oakland Research Institute, and CEO of FerroKin BioSciences.

Original post:
IP Watch: Abbott, University of Utah, Fluidigm, Roche, Quest, and Others Win US Patents

People in the News: Sherri Bale

Posted on by

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

Knome has added some new faces to its executive team, naming Jay Therrien as senior VP and head of global sales, Charles Abdalian as chief financial officer, and Adam Rosenberg as senior VP and head of corporate development.

Therrien was VP of commercial operations and sequencing at Life Technologies, and also had spent five years in various sales leadership roles at Illumina. Abdalian recently was senior VP and CFO of Molecular Insight Pharmaceuticals, and he was senior VP of finance and CFO at Coley Pharmaceutical. Rosenberg previously was an adviser for emerging life sciences companies, co-founder of Clean Membranes, and CEO of Link Medicine.

The company also has appointed Hugh Reinhoff to serve on its scientific advisory board. Reinhoff is currently a managing director of Life Science Venture Partners, an adjunct scientist at the Children's Hospital Oakland Research Institute, and CEO of FerroKin BioSciences.

Continue reading here:
People in the News: Sherri Bale

After Moving MammaPrint to FFPE Format, Agendia Sees Revenue Boost, Increasing Adoption

Posted on by

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

Knome has added some new faces to its executive team, naming Jay Therrien as senior VP and head of global sales, Charles Abdalian as chief financial officer, and Adam Rosenberg as senior VP and head of corporate development.

Therrien was VP of commercial operations and sequencing at Life Technologies, and also had spent five years in various sales leadership roles at Illumina. Abdalian recently was senior VP and CFO of Molecular Insight Pharmaceuticals, and he was senior VP of finance and CFO at Coley Pharmaceutical. Rosenberg previously was an adviser for emerging life sciences companies, co-founder of Clean Membranes, and CEO of Link Medicine.

The company also has appointed Hugh Reinhoff to serve on its scientific advisory board. Reinhoff is currently a managing director of Life Science Venture Partners, an adjunct scientist at the Children's Hospital Oakland Research Institute, and CEO of FerroKin BioSciences.

Continue reading here:
After Moving MammaPrint to FFPE Format, Agendia Sees Revenue Boost, Increasing Adoption

New Products: Roche's GS GType Primer Sets; Illumina's MyGenome; NextBio's NexBio Clinical

Posted on by

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

Knome has added some new faces to its executive team, naming Jay Therrien as senior VP and head of global sales, Charles Abdalian as chief financial officer, and Adam Rosenberg as senior VP and head of corporate development.

Therrien was VP of commercial operations and sequencing at Life Technologies, and also had spent five years in various sales leadership roles at Illumina. Abdalian recently was senior VP and CFO of Molecular Insight Pharmaceuticals, and he was senior VP of finance and CFO at Coley Pharmaceutical. Rosenberg previously was an adviser for emerging life sciences companies, co-founder of Clean Membranes, and CEO of Link Medicine.

The company also has appointed Hugh Reinhoff to serve on its scientific advisory board. Reinhoff is currently a managing director of Life Science Venture Partners, an adjunct scientist at the Children's Hospital Oakland Research Institute, and CEO of FerroKin BioSciences.

Continue reading here:
New Products: Roche's GS GType Primer Sets; Illumina's MyGenome; NextBio's NexBio Clinical

Illumina in Discussions with 100 Potential Clinical Customers for MiSeq, Plans Cancer Diagnostics

Posted on by

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

Knome has added some new faces to its executive team, naming Jay Therrien as senior VP and head of global sales, Charles Abdalian as chief financial officer, and Adam Rosenberg as senior VP and head of corporate development.

Therrien was VP of commercial operations and sequencing at Life Technologies, and also had spent five years in various sales leadership roles at Illumina. Abdalian recently was senior VP and CFO of Molecular Insight Pharmaceuticals, and he was senior VP of finance and CFO at Coley Pharmaceutical. Rosenberg previously was an adviser for emerging life sciences companies, co-founder of Clean Membranes, and CEO of Link Medicine.

The company also has appointed Hugh Reinhoff to serve on its scientific advisory board. Reinhoff is currently a managing director of Life Science Venture Partners, an adjunct scientist at the Children's Hospital Oakland Research Institute, and CEO of FerroKin BioSciences.

Read the rest here:
Illumina in Discussions with 100 Potential Clinical Customers for MiSeq, Plans Cancer Diagnostics

UNC Team Takes Proteomic Approach to Study Drug Resistance in Triple-Negative Breast Cancer

Posted on by

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

Knome has added some new faces to its executive team, naming Jay Therrien as senior VP and head of global sales, Charles Abdalian as chief financial officer, and Adam Rosenberg as senior VP and head of corporate development.

Therrien was VP of commercial operations and sequencing at Life Technologies, and also had spent five years in various sales leadership roles at Illumina. Abdalian recently was senior VP and CFO of Molecular Insight Pharmaceuticals, and he was senior VP of finance and CFO at Coley Pharmaceutical. Rosenberg previously was an adviser for emerging life sciences companies, co-founder of Clean Membranes, and CEO of Link Medicine.

The company also has appointed Hugh Reinhoff to serve on its scientific advisory board. Reinhoff is currently a managing director of Life Science Venture Partners, an adjunct scientist at the Children's Hospital Oakland Research Institute, and CEO of FerroKin BioSciences.

Continue reading here:
UNC Team Takes Proteomic Approach to Study Drug Resistance in Triple-Negative Breast Cancer

Mayo Researchers Use Whole-Genome Sequencing, Mouse 'Avatars' to Study Breast Cancer Resistance

Posted on by

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

Knome has added some new faces to its executive team, naming Jay Therrien as senior VP and head of global sales, Charles Abdalian as chief financial officer, and Adam Rosenberg as senior VP and head of corporate development.

Therrien was VP of commercial operations and sequencing at Life Technologies, and also had spent five years in various sales leadership roles at Illumina. Abdalian recently was senior VP and CFO of Molecular Insight Pharmaceuticals, and he was senior VP of finance and CFO at Coley Pharmaceutical. Rosenberg previously was an adviser for emerging life sciences companies, co-founder of Clean Membranes, and CEO of Link Medicine.

The company also has appointed Hugh Reinhoff to serve on its scientific advisory board. Reinhoff is currently a managing director of Life Science Venture Partners, an adjunct scientist at the Children's Hospital Oakland Research Institute, and CEO of FerroKin BioSciences.

Continue reading here:
Mayo Researchers Use Whole-Genome Sequencing, Mouse 'Avatars' to Study Breast Cancer Resistance

CARGO II Results on XDx's AlloMap Provide Validation for European Heart Transplant Market

Posted on by

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

Knome has added some new faces to its executive team, naming Jay Therrien as senior VP and head of global sales, Charles Abdalian as chief financial officer, and Adam Rosenberg as senior VP and head of corporate development.

Therrien was VP of commercial operations and sequencing at Life Technologies, and also had spent five years in various sales leadership roles at Illumina. Abdalian recently was senior VP and CFO of Molecular Insight Pharmaceuticals, and he was senior VP of finance and CFO at Coley Pharmaceutical. Rosenberg previously was an adviser for emerging life sciences companies, co-founder of Clean Membranes, and CEO of Link Medicine.

The company also has appointed Hugh Reinhoff to serve on its scientific advisory board. Reinhoff is currently a managing director of Life Science Venture Partners, an adjunct scientist at the Children's Hospital Oakland Research Institute, and CEO of FerroKin BioSciences.

See more here:
CARGO II Results on XDx's AlloMap Provide Validation for European Heart Transplant Market